Latest
-
Precision Cancer Medicines for Colon Cancer
Genomic testing identifies genetic targets that can be treated with precision cancer medicines avoiding chemotherapy
-
FDA Grants Accelerated Approval to New Targeted Treatment for Some HER2-mutated Lung Cancers
HYRNUO (sevabertinib), an oral precision therapy, has received FDA accelerated approval for adults with locally advanced or metastatic non-squamous NSCLC whose tumors have HER2 tyrosine kinase domain (TKD) activating mutations and who have already been treated with at least one systemic therapy.
Welcome to CancerConnect
CancerConnect is a unique resource that brings patients, caregivers, advocates and experts together – individuals benefit from a blend of expert-authored news and educational programming alongside a robust social network, providing insight into symptoms, diagnosis, and treatment and the support of other individuals being treated at some of the best cancer centers. CancerConnect offers users expert authored clinically-reviewed information and the perspective of their peers in a safe, objective space, helping to ensure they become empowered in their healthcare journey. Search the over 7000 articles on the management of cancer.
